Found 6 results[ Author] Title Type Year
Filters: Author is Aiello, LP [Clear All Filters]
Baseline Patient Characteristics in the PKC-DRS2 Trial: The Effect of The PKC-b Inhibitor Ruboxistaurin on Moderate Visual Loss. In 13th Congress of the European Society of Ophthalmology (SOE) and the 103rd Congress of German Society of Ophthalmology (DOG). presented at the 27/09/2005, Berlin, Germany. Retrieved from http://www.dog2005.org/images/soe_dog_programme_2005.pdf. (2005).
The Effect of the PKC b Inhibitor Ruboxistaurin on Moderate Visual Loss: The PKC-DRS2 Trial Baseline Characteristics and Preliminary Results. In American Academy of Ophthalmology. presented at the 14/10/2005, Chicago, IL. Retrieved from http://www.aao.org/meetings/annual_meeting/program/past-archive.cfm. (2005).
Initial Results of the Protein Kinase C b Inhibitor Diabetic Macular Edema Study (PKC-DMES). presented at the 2004.. (2004).
Initial results of the Protein Kinase C beta Inhibitor Diabetic Macular Edema Study (PKC-DMES). presented at the 2003.. (2003).